Clinical trials: CIN 2
High-Grade Squamous Intraepithelial Lesions, Neoplasm Regression, Spontaneous
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Consecutive inclusion and collection of information for all women attending the Cervical Disease Unit with an histological diagnosis of grade 2 or grade 3 CIN during the last 5 years, from January 2012 to December 2016, which…
- Conditions
- High-Grade Squamous Intraepithelial Lesions, Neoplasm Regression, Spontaneous, Disease Progression, Papillomavirus Infections
- Trial name
- NCT04115787
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
This is a Phase II study to evaluate the efficacy and safety of a human papilloma virus (HPV) therapeutic vaccine called PepCan (HPV 16 E6 peptides combined with Candida skin testing reagent called Candin®) in adult females over…
- Trial name
- NCT02481414
- Testing
- PepCan, Candin®
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Arkansas
CIN 2/3
Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral…
- Trial name
- NeoART-CIN (NCT07095478)
- Testing
- Artesunate
- Where
- 5 sites in Malaysia
- Volunteers
- 28 people
- Sponsor
- Metanoic Health Ltd.
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
CIN2
Conservative Management of CIN2 Lesions and Biomarkers Evaluation
Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion.
- Trial name
- NCT04687267
- Where
- 4 sites in Italy
- Volunteers
- 319 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer
- Trial name
- NCT07468695
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- Kenya
- Volunteers
- 300 people
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Intraepithelial Neoplasia
Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9
This study evaluates the impact on disease relapse of presurgical 9-valent HPV vaccination versus placebo vaccination in women treated with LEEP (loop electrosurgical excision procedure) for CIN2+ (high grade cervical…
- Trial name
- HOPE9 (NCT03848039)
- Testing
- Gardasil-9
- Volunteers
- 1,220 people
- Sponsor
- Alessandro Ghelardi
Cervical Cancer, Precancerous Condition
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- SAGE (NCT00629577)
- Testing
- microarray analysis, flow cytometry, biopsy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Cervical Intraepithelial Neoplasia Grade 2/3
Effectiveness of Cervical Screening in HPV Vaccinated Women
The main objective of the study is to identify whether or not being informed infrequently results about screening is: 1) At least as safe and accurate as frequently obtaining all information from the present combination of…
- Trial name
- HPV-004 (NCT02149030)
- Testing
- Cytological screening in A1 and A3
- Where
- 31 sites in Finland
- Volunteers
- 6,958 people, healthy volunteers welcome
- Sponsor
- Tampere University
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement
Introduction Cervical intraepithelial neoplasia CIN1 (low grade), CIN2 (moderate grade), CIN3 (severe grade) defines cervical precancer lesions derived from the squamous epithelial cell line.
- Trial name
- NCT05049252
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Cervical Intraepithelial Neoplasia, Human Papillomavirus
A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
Background: The Mississippi Delta (which includes the counties along the Mississippi River) is one of the poorest areas in the United States.
- Trial name
- NCT01058148
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, CIN2
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
The purpose of this study is to explore whether an anti-cancer medication (5-fluorouracil cream) placed in the vagina after a surgical excision procedure is an acceptable and useful form of treatment for cervical precancer among…
- Conditions
- Cervical Cancer, CIN2, CIN3, Human Immunodeficiency Virus
- Trial name
- ACT 2 (NCT05413811)
- Testing
- 5 Fluorouracil (5 FU) Cream
- Where
- South Africa
- Volunteers
- 180 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer, Precancerous Condition
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
RATIONALE: Studying Pap smears in the laboratory from women with atypical glandular cells of unspecified significance may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898144
- Testing
- Papanicolaou test, laboratory biomarker analysis
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Precancerous Condition
Fenretinide in Treating Patients With Cervical Neoplasia
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer.
- Trial name
- NCT00003075
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Precancerous Condition
Spectroscopy in Diagnosing Dysplasia and Neoplasia in the Cervix in Women Undergoing Colposcopy
RATIONALE: New diagnostic procedures, such as spectroscopy, may be a less invasive way to check for dysplasia and neoplasia in the cervix.
- Trial name
- NCT00632190
- Testing
- fluorophotometry, colposcopic biopsy, colposcopy
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Cervical Intraepithelial Neoplasia
Management of Cervical Intraepithelial Neoplasia Grade 2
The aim of this study was to compare two management options for CIN 2. This randomized clinical trial performed between 2003 and 2006.
- Trial name
- CIN2 (NCT00733109)
- Testing
- Excision of the lesion, Follow-up for spontaneous regression of the lesion
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Universidade Cidade de Sao Paulo
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System)…
- Trial name
- NCT07454915
- Testing
- PVX4 Combination Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 138 people
- Sponsor
- PapiVax Biotech, Inc.
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Human Papillomavirus (HPV)
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT01188850
- Testing
- VGX-3100
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- Inovio Pharmaceuticals